Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

ACORDA THERAPEUTICS INC (ACOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
24.75(c) 24.95(c) 25.6(c) 25.1(c) 25.8(c) Last
386 565 393 519 726 821 863 989 639 170 Volume
+2.91% +0.81% +2.61% -1.95% +2.79% Change
More quotes
Financials ($)
Sales 2018 404 M
EBIT 2018 -19,8 M
Net income 2018 -10,3 M
Finance 2018 25,5 M
Yield 2018 -
Sales 2019 209 M
EBIT 2019 -120 M
Net income 2019 -163 M
Debt 2019 127 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 2,84x
EV / Sales2019 6,23x
Capitalization 1 173 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
02/15ACORDA THERAPEUTICS : to Present at the Leerink Partners 7th Annual Global Healt..
AQ
02/15ACORDA THERAPEUTICS : reports 4Q loss
AQ
02/15ACORDA THERAPEUTICS INC : Acorda Therapeutics, Inc. to Host Earnings Call
AC
02/15ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Fourth Quarter ..
BU
02/08ACORDA THERAPEUTICS : to Present at the Leerink Partners 7th Annual Global Healt..
BU
02/02ACORDA THERAPEUTICS : Fourth Quarter/Year End 2017 Update
BU
02/01ACORDA THERAPEUTICS : Researchers at Acorda Therapeutics Have Reported New Data ..
AQ
01/22ACORDA THERAPEUTICS INC : Today’s Research Reports on Trending Tickers: Acorda T..
AC
01/22ACORDA THERAPEUTICS INC : Blog Exposure - Acorda Therapeutics’ Stock Surges Amid..
AC
01/19MARKET SNAPSHOT : S&P 500, Nasdaq Add To String Of 2018 Records As Investors Sha..
DJ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07:32aAcorda Therapeutics $ACOR Upgraded to “Hold” at ValuEngine  
02/16Acorda Therapeutics $ACOR Posts Earnings Results, Misses Estimates By $0.44 E.. 
02/16Acorda Therapeutics Receives a Hold from Oppenheimer $ACOR  
02/16Upgrades 2/16: $ACOR $ALRM $ALSN $APRN $AVH $CAMP $CALA $COWN $DBVT $ECA $EQC.. 
02/15Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End.. 
More tweets
Qtime:121
News from SeekingAlpha
02/16Acorda Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides 
02/16Premarket analyst action - healthcare 
02/15Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2017 Results - Earnings Call .. 
02/15Acorda Therapeutics Q4 revenues up 34%; updates guidance 
02/15Acorda Therapeutics misses by $0.44, beats on revenue 
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 24,6 $
Spread / Average Target -2,2%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
Andrew R. Blight Chief Scientific Officer
Richard P. Batycky Chief Technology Officer
Burkhard Blank Chief Medical Officer
Sandra Panem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC19.35%1 173
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055